颅内肿瘤可以引起阻塞性脑积水（OH）。最常采取的治疗方法是经脑室脑膜翻修术（VS）或内窥镜第三脑室成形术（ETV）。在本研究中，我们提出了采用立体定向第三脑室成形术内窦分流（sTVIP）作为替代治疗方案，并评估其安全性和有效性。在这项单中心、回顾性分析中，评估了2010年1月至2021年12月间因肿瘤形成导致OH的所有患者的临床症状、与手术相关的并发症和无需修复的生存率。对38名患者（11名女性，27名男性）的临床记录进行了分析，平均年龄为40岁（范围为5-88岁）。OH主要（92%的患者）是由原发性脑肿瘤引起的（除了3例转移病例）。sTVIP术后，74.2%的患者出现症状改善。术前头痛是术后症状改善的显著预测因子（OR 26.25；95% CI 4.1-521.1；p = 0.0036）。在2例（5.3%）患者的立体定向轨迹上检测到无症状出血。一名患者因脑脊液瘘需要局部修复（2.6%）；另一名患者需进行二次手术，将导管连接到瓣膜/腹腔导管，以纠正脑脊液吸收不良。然而，在其余37名患者中，在中位数为12个月（IQR为3-32个月）的随访期内，保持了分流独立。未观察到与手术相关的死亡。sTVIP可显著控制症状，并与低手术并发症率相关，以及随访期间高的经脑室腹腔分流独立率。因此，即使在预脑桥间隔狭窄的情况下，sTVIP是一种高效、微创的肿瘤相关阻塞性脑积水治疗选择。© 2023. 作者。

Intracranial tumors can cause obstructive hydrocephalus (OH). Most often, symptomatic treatment is pursued through ventriculoperitoneal shunt (VS) or endoscopic third ventriculostomy (ETV). In this study, we propose stereotactic third ventriculostomy with internal shunt placement (sTVIP) as an alternative treatment option and assess its safety and efficacy.In this single-center, retrospective analysis, clinical symptoms, procedure-related complications, and revision-free survival of all patients with OH due to tumor formations treated by sTVIP between January 2010 and December 2021 were evaluated.Clinical records of thirty-eight patients (11 female, 27 male) with a mean age of 40 years (range 5-88) were analyzed. OH was predominantly (in 92% of patients) caused by primary brain tumors (with exception of 3 cases with metastases). Following sTVIP, 74.2% of patients experienced symptomatic improvement. Preoperative headache was a significant predictor of postoperative symptomatic improvement (OR 26.25; 95% CI 4.1-521.1; p = 0.0036). Asymptomatic hemorrhage was detected along the stereotactic trajectory in 2 cases (5.3%). One patient required local revision due to CSF fistula (2.6%); another patient had to undergo secondary surgery to connect the catheter to a valve/abdominal catheter due to CSF malabsorption. However, in the remaining 37 patients, shunt independence was maintained during a median follow-up period of 12 months (IQR 3-32 months). No surgery-related mortality was observed.sTVIP led to a significant symptom control and was associated with low operative morbidity, along with a high rate of ventriculoperitoneal shunt independency during the follow-up period. Therefore, sTVIP constitutes a highly effective and minimally invasive treatment option for tumor-associated obstructive hydrocephalus, even in cases with a narrow prepontine interval.© 2023. The Author(s).